Key drivers include expanding Cabo’s indications and advancing Zanza pivotal trials. The Cabo franchise delivered strong growth, with Q4 U.S. net product revenues of $515 million, representing a ...

Q4 2024 Earnings Call Transcript February 11, 2025 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.48 EPS, ...

Some folks say the journey is more important than the destination, but most travellers would beg to differ. Indeed, who ...

Citi raised the firm’s price target on Exelixis (EXEL) to $45 from $38 and keeps a Buy rating on the shares following the Q4 report. The ...

Exelixis Inc (EXEL) reports robust financial performance and outlines ambitious goals for its oncology portfolio amid market ...

Zanzalintinib stands out as Exelixis’ most clinically advanced asset with potential to become a primary contributor in the medium to long term, says the analyst, who is incorporating zanza into ...

Exelixis has made significant strides in establishing itself as a multi-compound, multi-franchise oncology business.